Advertisement
Screener

United Therapeutics Corporation (UTHR) Increase (Decrease) in Accounts Payable and Accrued Liabilities

2.8 / 5 stars · 68/120 Roast Me

United Therapeutics Corporation Increase (Decrease) in Accounts Payable and Accrued Liabilities

United Therapeutics Corporation (UTHR) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of -$16.70 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.

Financial Statements › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2026-08-05

  • United Therapeutics Corporation increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-06-30 was -$4.00M, a 108.68% decline year-over-year.
  • United Therapeutics Corporation increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-03-31 was -$12.70M.
  • United Therapeutics Corporation increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-12-31 was $23.20M.
  • United Therapeutics Corporation increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-09-30 was $31.20M, a 5.45% decline year-over-year.
  • United Therapeutics Corporation increase (decrease) in accounts payable and accrued liabilities for fiscal 2025 was $97.90M, a 129.27% increase from fiscal 2024.
  • United Therapeutics Corporation increase (decrease) in accounts payable and accrued liabilities for fiscal 2024 was $42.70M, a 25.22% decline from fiscal 2023.
  • United Therapeutics Corporation increase (decrease) in accounts payable and accrued liabilities for fiscal 2023 was $57.10M, a 28.31% increase from fiscal 2022.
  • United Therapeutics Corporation increase (decrease) in accounts payable and accrued liabilities for fiscal 2022 was $44.50M.
Period endIncrease (Decrease) in Accounts Payable and Accrued Liabilities 3 monthIncrease (Decrease) in Accounts Payable and Accrued Liabilities 3 month as first filedIncrease (Decrease) in Accounts Payable and Accrued Liabilities 6 monthIncrease (Decrease) in Accounts Payable and Accrued Liabilities 6 month as first filedIncrease (Decrease) in Accounts Payable and Accrued Liabilities 9 monthIncrease (Decrease) in Accounts Payable and Accrued Liabilities 9 month as first filedIncrease (Decrease) in Accounts Payable and Accrued Liabilities 12 monthIncrease (Decrease) in Accounts Payable and Accrued Liabilities 12 month as first filed
2026-06-30-$4.00M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05
-$16.70M
10-Q · filed 2026-08-05
$6.50M
derived: sum of 3 quarters · filed 2026-08-05
$37.70M
derived: sum of 4 quarters · filed 2026-08-05
2026-03-31-$12.70M
10-Q · filed 2026-05-06
$10.50M
derived: sum of 2 quarters · filed 2026-05-06
$41.70M
derived: sum of 3 quarters · filed 2026-05-06
$87.80M
derived: sum of 4 quarters · filed 2026-08-05
2025-12-31$23.20M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25
$54.40M
derived: sum of 2 quarters · filed 2026-02-25
$100.50M
derived: sum of 3 quarters · filed 2026-08-05
$97.90M
10-K · filed 2026-02-25
2025-09-30$31.20M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29
$77.30M
derived: sum of 2 quarters · filed 2026-08-05
$74.70M
10-Q · filed 2025-10-29
$56.70M
derived: sum of 4 quarters · filed 2026-08-05
2025-06-30$46.10M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05
$43.50M
10-Q · filed 2026-08-05
$25.50M
derived: sum of 3 quarters · filed 2026-08-05
$58.50M
derived: sum of 4 quarters · filed 2026-08-05
2025-03-31-$2.60M
10-Q · filed 2026-05-06
-$20.60M
derived: sum of 2 quarters · filed 2026-05-06
$12.40M
derived: sum of 3 quarters · filed 2026-05-06
$38.20M
derived: sum of 4 quarters · filed 2026-05-06
2024-12-31-$18.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25
$15.00M
derived: sum of 2 quarters · filed 2026-02-25
$40.80M
derived: sum of 3 quarters · filed 2026-02-25
$42.70M
10-K · filed 2026-02-25
2024-09-30$33.00M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29
$58.80M
derived: sum of 2 quarters · filed 2025-10-29
$60.70M
10-Q · filed 2025-10-29
$37.60M
derived: sum of 4 quarters · filed 2026-02-25
2024-06-30$25.80M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-30
$27.70M
10-Q · filed 2025-07-30
$4.60M
derived: sum of 3 quarters · filed 2026-02-25
$44.00M
derived: sum of 4 quarters · filed 2026-02-25
2024-03-31$1.90M
10-Q · filed 2025-04-30
-$21.20M
derived: sum of 2 quarters · filed 2026-02-25
$18.20M
derived: sum of 3 quarters · filed 2026-02-25
$56.20M
derived: sum of 4 quarters · filed 2026-02-25
2023-12-31-$23.10M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25
$16.30M
derived: sum of 2 quarters · filed 2026-02-25
$54.30M
derived: sum of 3 quarters · filed 2026-02-25
$57.10M
10-K · filed 2026-02-25
2023-09-30$39.40M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30
$77.40M
derived: sum of 2 quarters · filed 2024-10-30
$80.20M
10-Q · filed 2024-10-30
$89.30M
derived: sum of 4 quarters · filed 2025-02-26
2023-06-30$38.00M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-31
$40.80M
10-Q · filed 2024-07-31
$49.90M
derived: sum of 3 quarters · filed 2025-02-26
$72.20M
derived: sum of 4 quarters · filed 2025-02-26
2023-03-31$2.80M
10-Q · filed 2024-05-01
$11.90M
derived: sum of 2 quarters · filed 2025-02-26
$34.20M
derived: sum of 3 quarters · filed 2025-02-26
$58.10M
derived: sum of 4 quarters · filed 2025-02-26
2022-12-31$9.10M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26
$31.40M
derived: sum of 2 quarters · filed 2025-02-26
$55.30M
derived: sum of 3 quarters · filed 2025-02-26
$44.50M
10-K · filed 2025-02-26
2022-09-30$22.30M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01
$46.20M
derived: sum of 2 quarters · filed 2023-11-01
$35.40M
10-Q · filed 2023-11-01
$900.00K
derived: sum of 4 quarters · filed 2024-02-21
2022-06-30$23.90M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02
$13.10M
10-Q · filed 2023-08-02
-$21.40M
derived: sum of 3 quarters · filed 2024-02-21
-$1.60M
derived: sum of 4 quarters · filed 2024-02-21
2022-03-31-$10.80M
10-Q · filed 2023-05-03
-$45.30M
derived: sum of 2 quarters · filed 2024-02-21
-$25.50M
derived: sum of 3 quarters · filed 2024-02-21
$1.70M
derived: sum of 4 quarters · filed 2024-02-21
2021-12-31-$34.50M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21
-$14.70M
derived: sum of 2 quarters · filed 2024-02-21
$12.50M
derived: sum of 3 quarters · filed 2024-02-21
-$12.50M
10-K · filed 2024-02-21
2021-09-30$19.80M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02
$47.00M
derived: sum of 2 quarters · filed 2022-11-02
$22.00M
10-Q · filed 2022-11-02
$32.70M
derived: sum of 4 quarters · filed 2023-02-22
2021-06-30$27.20M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03
$2.20M
10-Q · filed 2022-08-03
$12.90M
derived: sum of 3 quarters · filed 2023-02-22
$38.20M
derived: sum of 4 quarters · filed 2023-02-22
2021-03-31-$25.00M
10-Q · filed 2022-05-04
-$14.30M
derived: sum of 2 quarters · filed 2023-02-22
$11.00M
derived: sum of 3 quarters · filed 2023-02-22
$32.40M
derived: sum of 4 quarters · filed 2023-02-22
2020-12-31$10.70M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22
$36.00M
derived: sum of 2 quarters · filed 2023-02-22
$57.40M
derived: sum of 3 quarters · filed 2023-02-22
$38.60M
10-K · filed 2023-02-22
2020-09-30$25.30M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03
$46.70M
derived: sum of 2 quarters · filed 2021-11-03
$27.90M
10-Q · filed 2021-11-03
$16.50M
derived: sum of 4 quarters · filed 2022-02-24
2020-06-30$21.40M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04
$2.60M
10-Q · filed 2021-08-04
-$8.80M
derived: sum of 3 quarters · filed 2022-02-24
-$10.70M
derived: sum of 4 quarters · filed 2022-02-24
2020-03-31-$18.80M
10-Q · filed 2021-05-05
-$30.20M
derived: sum of 2 quarters · filed 2022-02-24
-$32.10M
derived: sum of 3 quarters · filed 2022-02-24
-$7.40M
derived: sum of 4 quarters · filed 2022-02-24
2019-12-31-$11.40M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24
-$13.30M
derived: sum of 2 quarters · filed 2022-02-24
$11.40M
derived: sum of 3 quarters · filed 2022-02-24
-$16.30M
10-K · filed 2022-02-24
2019-09-30-$1.90M
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-28
$22.80M
derived: sum of 2 quarters · filed 2020-10-28
-$4.90M
10-Q · filed 2020-10-28
-$37.80M
derived: sum of 4 quarters · filed 2021-02-24
2019-06-30$24.70M
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-29
-$3.00M
10-Q · filed 2020-07-29
-$35.90M
derived: sum of 3 quarters · filed 2021-02-24
-$53.90M
derived: sum of 4 quarters · filed 2021-02-24
2019-03-31-$27.70M
10-Q · filed 2020-04-29
-$60.60M
derived: sum of 2 quarters · filed 2021-02-24
-$78.60M
derived: sum of 3 quarters · filed 2021-02-24
-$60.70M
derived: sum of 4 quarters · filed 2021-02-24
2018-12-31-$32.90M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24
-$50.90M
derived: sum of 2 quarters · filed 2021-02-24
-$33.00M
derived: sum of 3 quarters · filed 2021-02-24
-$11.00M
10-K · filed 2021-02-24
2018-09-30-$18.00M
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-30
-$100.00K
derived: sum of 2 quarters · filed 2019-10-30
$21.90M
10-Q · filed 2019-10-30
$50.20M
derived: sum of 4 quarters · filed 2020-02-26
2018-06-30$17.90M
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-31
$39.90M
10-Q · filed 2019-07-31
$68.20M
derived: sum of 3 quarters · filed 2020-02-26
$85.30M
derived: sum of 4 quarters · filed 2020-02-26
2018-03-31$22.00M
10-Q · filed 2019-05-01
$50.30M
derived: sum of 2 quarters · filed 2020-02-26
$67.40M
derived: sum of 3 quarters · filed 2020-02-26
$89.30M
derived: sum of 4 quarters · filed 2020-02-26
2017-12-31$28.30M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26
$45.40M
derived: sum of 2 quarters · filed 2020-02-26
$67.30M
derived: sum of 3 quarters · filed 2020-02-26
$66.20M
10-K · filed 2020-02-26
2017-09-30$17.10M
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-31
$39.00M
derived: sum of 2 quarters · filed 2018-10-31
$37.90M
10-Q · filed 2018-10-31
$24.60M
derived: sum of 4 quarters · filed 2019-02-27
2017-06-30$21.90M
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-01
$20.80M
10-Q · filed 2018-08-01
$7.50M
derived: sum of 3 quarters · filed 2019-02-27
$1.60M
derived: sum of 4 quarters · filed 2019-02-27
2017-03-31-$1.10M
10-Q · filed 2018-05-02
-$14.40M
derived: sum of 2 quarters · filed 2019-02-27
-$20.30M
derived: sum of 3 quarters · filed 2019-02-27
-$1.00M
derived: sum of 4 quarters · filed 2019-02-27
2016-12-31-$13.30M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27
-$19.20M
derived: sum of 2 quarters · filed 2019-02-27
$100.00K
derived: sum of 3 quarters · filed 2019-02-27
$600.00K
10-K · filed 2019-02-27
2016-09-30-$5.90M
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-25
$13.40M
derived: sum of 2 quarters · filed 2017-10-25
$13.90M
10-Q · filed 2017-10-25
$5.10M
derived: sum of 4 quarters · filed 2018-02-21
2016-06-30$19.30M
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-07-27
$19.80M
10-Q · filed 2017-07-27
$11.00M
derived: sum of 3 quarters · filed 2018-02-21
$13.50M
derived: sum of 4 quarters · filed 2018-02-21
2016-03-31$500.00K
10-Q · filed 2017-04-26
-$8.30M
derived: sum of 2 quarters · filed 2018-02-21
-$5.80M
derived: sum of 3 quarters · filed 2018-02-21
$12.80M
derived: sum of 4 quarters · filed 2018-02-21
2015-12-31-$8.80M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-21
-$6.30M
derived: sum of 2 quarters · filed 2018-02-21
$12.30M
derived: sum of 3 quarters · filed 2018-02-21
$17.00M
10-K · filed 2018-02-21
$16.97M
10-K · filed 2016-02-25
2015-09-30$2.50M
derived: 10-Q 9 month − 10-Q 6 month · filed 2016-10-27
$21.10M
derived: sum of 2 quarters · filed 2016-10-27
$25.80M
10-Q · filed 2016-10-27
$25.82M
10-Q · filed 2015-10-27
-$16.86M
derived: sum of 4 quarters · filed 2017-02-22
2015-06-30$18.60M
derived: 10-Q 6 month − 10-Q 3 month · filed 2016-07-28
$23.30M
10-Q · filed 2016-07-28
$23.33M
10-Q · filed 2015-07-28
-$19.36M
derived: sum of 3 quarters · filed 2017-02-22
-$3.52M
derived: sum of 4 quarters · filed 2017-02-22
2015-03-31$4.70M
10-Q · filed 2016-04-28
$4.75M
10-Q · filed 2015-04-28
-$37.95M
derived: sum of 2 quarters · filed 2017-02-22
-$22.12M
derived: sum of 3 quarters · filed 2017-02-22
-$13.82M
derived: sum of 4 quarters · filed 2017-02-22
2014-12-31-$42.66M
derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-22
-$26.82M
derived: sum of 2 quarters · filed 2017-02-22
-$18.52M
derived: sum of 3 quarters · filed 2017-02-22
-$6.80M
10-K · filed 2017-02-22
-$6.75M
10-K · filed 2015-02-24
2014-09-30$15.84M
derived: 10-Q 9 month − 10-Q 6 month · filed 2015-10-27
$24.13M
derived: sum of 2 quarters · filed 2015-10-27
$35.85M
10-Q · filed 2015-10-27
$30.73M
derived: sum of 4 quarters · filed 2016-02-25
2014-06-30$8.29M
derived: 10-Q 6 month − 10-Q 3 month · filed 2015-07-28
$20.02M
10-Q · filed 2015-07-28
$14.89M
derived: sum of 3 quarters · filed 2016-02-25
$20.76M
derived: sum of 4 quarters · filed 2016-02-25
2014-03-31$11.72M
10-Q · filed 2015-04-28
$6.60M
derived: sum of 2 quarters · filed 2016-02-25
$12.47M
derived: sum of 3 quarters · filed 2016-02-25
$23.15M
derived: sum of 4 quarters · filed 2016-02-25
2013-12-31-$5.13M
derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-25
$744.00K
derived: sum of 2 quarters · filed 2016-02-25
$11.42M
derived: sum of 3 quarters · filed 2016-02-25
$7.51M
10-K · filed 2016-02-25
2013-09-30$5.87M
derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-28
$16.55M
derived: sum of 2 quarters · filed 2014-10-28
$12.63M
10-Q · filed 2014-10-28
-$3.05M
derived: sum of 4 quarters · filed 2015-02-24
2013-06-30$10.68M
derived: 10-Q 6 month − 10-Q 3 month · filed 2014-07-29
$6.76M
10-Q · filed 2014-07-29
-$8.92M
derived: sum of 3 quarters · filed 2015-02-24
2013-03-31-$3.92M
10-Q · filed 2014-04-29
-$19.60M
derived: sum of 2 quarters · filed 2015-02-24
2012-12-31-$15.68M
derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-24
-$22.80M
10-K · filed 2015-02-24
2012-09-30-$7.12M
10-Q · filed 2013-10-29
2011-12-31$20.25M
10-K · filed 2014-02-25

Similar stocks

Stock NameCountryMarket CapPE Ratio
Viatris Inc (VTRS)United States$20.008B-0.00
Royalty Pharma plc (RPRX)United States$22.628B
Jazz Pharmaceuticals plc (JAZZ)$15.333B16.07
Roivant Sciences Ltd. (ROIV)$26.105B-96.08
INSMED Inc (INSM)United States$26.566B-26.60
Summit Therapeutics Inc. (SMMT)United States$13.071B-13.21
BridgeBio Pharma, Inc. (BBIO)United States$12.947B-20.72
CORCEPT THERAPEUTICS INC (CORT)United States$12.804B169.10
BIOMARIN PHARMACEUTICAL INC (BMRN)United States$11.879B151.80
MADRIGAL PHARMACEUTICALS, INC. (MDGL)United States$11.859B-38.17